Science Explorer Back to mapMap
Discussion
Company · Dundee · United Kingdom

Cyclacel Pharmaceuticals (United Kingdom)

cyclacel.comROR OpenAlex
Research works
94
▼ 46% vs 2018-21
Citations
4.1k
43.5 per fractional work
Top-10% rate
11.7%
all institutions 10.0%
Open access
22%
world 40%
International
20%
world 18%
Cyclacel Pharmaceuticals (United Kingdom)

Not ranked overall: Cyclacel Pharmaceuticals (United Kingdom) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Cyclacel Pharmaceuticals (United Kingdom) work in?

In all years, 48% of research at Cyclacel Pharmaceuticals (United Kingdom) is in Health Sciences, 43% in Life Sciences. Its largest fields are Medicine (48%), Biochemistry, Genetics and Molecular Biology (40%), Chemistry (4%). It does 2.5× the world's share of Life Sciences.

Health Sciences: 45 fractional works · 47.7% of its workMedicine: 45 fractional works · 47.7% of its workOncology: 22 fractional works · 23.0% of its workPulmonary and Respiratory Medicine: 11 fractional works · 11.4% of its workGenetics: 3 fractional works · 3.5% of its workHematology: 3 fractional works · 3.4% of its workPathology and Forensic Medicine: 2 fractional works · 2.2% of its workInfectious Diseases: 1 fractional works · 1.2% of its workPharmacology: 1 fractional works · 0.9% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 0.8% of its workNephrology: 0 fractional works · 0.4% of its workSurgery: 0 fractional works · 0.4% of its workSmaller subfields together: 1 fractional works · 0.5% of its workLife Sciences: 40 fractional works · 42.7% of its workBiochemistry, Genetics and Molecular Biology: 38 fractional works · 40.4% of its workMolecular Biology: 24 fractional works · 26.1% of its workCell Biology: 8 fractional works · 8.7% of its workCancer Research: 3 fractional works · 2.9% of its workBiotechnology: 1 fractional works · 1.2% of its workGenetics: 1 fractional works · 0.8% of its workBiochemistry: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.1% of its workPharmacology: 1 fractional works · 0.7% of its workPharmaceutical Science: 0 fractional works · 0.4% of its workImmunology and Microbiology: 1 fractional works · 1.0% of its workImmunology: 0 fractional works · 0.5% of its workMicrobiology: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNeuroscience: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 0 fractional works · 0.1% of its workPhysical Sciences: 7 fractional works · 7.8% of its workChemistry: 4 fractional works · 4.5% of its workOrganic Chemistry: 4 fractional works · 4.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workComputer Science: 1 fractional works · 1.5% of its workComputational Theory and Mathematics: 1 fractional works · 1.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workMaterials Science: 1 fractional works · 1.4% of its workMaterials Chemistry: 1 fractional works · 0.7% of its workBiomaterials: 0 fractional works · 0.4% of its workPolymers and Plastics: 0 fractional works · 0.4% of its workEngineering: 0 fractional works · 0.4% of its workAerospace Engineering: 0 fractional works · 0.4% of its workMathematics: 0 fractional works · 0.1% of its workSocial Sciences: 2 fractional works · 1.8% of its workSocial Sciences: 2 fractional works · 1.8% of its workAnthropology: 0 fractional works · 0.4% of its workPolitical Science and International Relations: 0 fractional works · 0.4% of its workSociology and Political Science: 0 fractional works · 0.4% of its workTransportation: 0 fractional works · 0.4% of its workUrban Studies: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.0% of its workALL ITS WORKCyclacelPharmaceuticals…94fractional works, all years
Life Sciences43%Physical Sciences8%Health Sciences48%Social Sciences2%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Medicine4547.7%
    1. Biochemistry, Genetics and Molecular Biology3840.4%
    2. Pharmacology, Toxicology and Pharmaceutics11.1%
    3. Immunology and Microbiology11.0%
    4. Neuroscience00.2%
    5. Agricultural and Biological Sciences00.1%
    1. Chemistry44.5%
    2. Computer Science11.5%
    3. Materials Science11.4%
    4. Engineering00.4%
    5. Mathematics00.1%
    1. Social Sciences21.8%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Cyclacel Pharmaceuticals (United Kingdom)?

Ranked on the quality score, Sheelagh Frame, Athos Gianella-Borradori and Daniella I. Zheleva lead among researchers whose main affiliation is Cyclacel Pharmaceuticals (United Kingdom).

  1. 1 Sheelagh Frame United Kingdom · #268,145 worldwide 6.5k citations · 48 works
  2. 2 Athos Gianella-Borradori United Kingdom · #491,534 worldwide 3.8k citations · 61 works
  3. 3 Daniella I. Zheleva United Kingdom · #568,398 worldwide 3k citations · 90 works
  4. 4 Simon R. Green United Kingdom · #588,730 worldwide 3.9k citations · 105 works
  5. 5 Judy H. Chiao United Kingdom · #663,709 worldwide 4.3k citations · 50 works
  6. 6 Campbell McInnes United Kingdom · #1,464,210 worldwide 916 citations · 27 works
  7. 7 David G. BLAKE United Kingdom · #1,589,810 worldwide 1.3k citations · 52 works
  8. 8 Steven J. McClue United Kingdom · #1,995,361 worldwide 1.6k citations · 35 works
  9. 9 Chiara Saladino United Kingdom · #2,571,677 worldwide 296 citations · 24 works
  10. 10 Wayne Jackson United Kingdom · #2,654,084 worldwide 856 citations · 27 works
All ranked researchers at Cyclacel Pharmaceuticals (United Kingdom)

What are the most cited papers from Cyclacel Pharmaceuticals (United Kingdom)?

The most cited paper from Cyclacel Pharmaceuticals (United Kingdom) is "In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine)" (Steven J. McClue, David G. BLAKE, Rosemary G. Clarke et al., 2002), with 367 citations. Next come "Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients" (336) and "An in vitro model of angiogenesis: Basic features" (311).

Most cited papers
#PaperReleasedCitations
1 In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) Steven J. McClue, David G. BLAKE, Rosemary G. Clarke et al. · International Journal of Cancer Open access 9 Oct 2002 367
2 Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients Maurizio Scaltriti, Pieter J.A. Eichhorn, Javier Cortés et al. · Proceedings of the National Academy of Sciences Open access 14 Feb 2011 336
3 An in vitro model of angiogenesis: Basic features Eileen Bishop, Graham T. Bell, Stephen Bloor et al. · Angiogenesis Dec 1999 311
4 Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1 David E. MacCallum, Jean Melville, Sheelagh Frame et al. · Cancer Research Open access 15 Jun 2005 288
5 A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days Charlotte Benson, Jeff D White, Johann Sebastian De Bono et al. · British Journal of Cancer Open access 19 Dec 2006 263
All 60 most cited papers, with filters and sorting

Which keywords describe research at Cyclacel Pharmaceuticals (United Kingdom)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Therapy, Mutation, Apoptosis, Tumor Suppression, Cell Cycle, p53, Metastatic Breast Cancer and Breast Cancer.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Therapy30▲ 51×9 topics
  2. Apoptosis17▲ 46×2 topics
  3. Mutation17▲ 114×2 topics
  4. Tumor Suppression16▲ 152×2 topics
  5. Cell Cycle16▲ 300×1 topic
  6. p5316▲ 397×1 topic
  7. Metastatic Breast Cancer11▲ 174×2 topics
  8. Breast Cancer10▲ 39×4 topics
  9. Cell Cycle Control10▲ 405×2 topics
  10. CDK4/6 Inhibitors9▲ 633×1 topic
  11. Palbociclib9▲ 633×1 topic
  12. Cell Division8▲ 234×1 topic
  13. Microtubules8▲ 234×1 topic
  14. Prognostic Factors7▲ 16×4 topics
  15. Drug Discovery6▲ 15×5 topics
  16. Cancer4▲ 3.1×11 topics
  17. Chemotherapy4▲ 5.9×9 topics
  18. Rituximab4▲ 25×2 topics
  19. Therapeutic Targets4▲ 17×3 topics
  20. Proteasome Inhibitors3▲ 50×2 topics
  21. Transcriptional Regulation3▲ 14×3 topics
  22. Chronic Lymphocytic Leukemia3▲ 71×1 topic
  23. Genomic Aberrations3▲ 71×1 topic
  24. Proteasome3▲ 79×1 topic
  25. Ubiquitin3▲ 79×1 topic
  26. BET Bromodomains3▲ 143×1 topic
  27. Gene Therapy3▲ 11×3 topics
  28. PROTACs3▲ 143×1 topic
  29. Foldamers3▲ 34×1 topic
  30. Homologous Recombination3▲ 42×2 topics
  31. Peptide Synthesis3▲ 34×1 topic
  32. Protein-Protein Interactions3▲ 26×2 topics
  33. Tumor Microenvironment3▲ 7.9×3 topics
  34. Cancer Progression2▲ 11×3 topics
  35. Tumor Hypoxia2▲ 29×2 topics
  36. AML2▲ 53×1 topic
  37. Acute Myeloid Leukemia2▲ 53×1 topic
  38. Molecular Docking2▲ 18×3 topics
  39. Genomic Stability2▲ 24×2 topics
  40. Inhibitors2▲ 32×2 topics

Which research topics does Cyclacel Pharmaceuticals (United Kingdom) publish most on?

By volume in 2022-now: Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Cancer-related Molecular Pathways and CAR-T cell therapy research.

Chronic Lymphocytic Leuk…1Chronic Lymphocytic Leukemia Research: 1 fractional worksAdvanced Breast Cancer T…1Advanced Breast Cancer Therapies: 1 fractional worksCancer-related Molecular Pathways: 0 fractional worksCAR-T cell therapy research: 0 fractional worksCancer Treatment and Pharmacology: 0 fractional worksT-cell and Retrovirus Studies: 0 fractional worksCancer, Lipids, and Metabolism: 0 fractional worksColorectal Cancer Treatments and Studies: 0 fractional worksCancer Cells and Metastasis: 0 fractional works
GeneticsPulmonary and Respiratory MedicineOncologyImmunology1 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Chronic Lymphocytic Leukemia Research Genetics 1 works
  2. 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
  3. 3 Cancer-related Molecular Pathways Oncology 0 works
  4. 4 CAR-T cell therapy research Oncology 0 works
  5. 5 Cancer Treatment and Pharmacology Oncology 0 works
  6. 6 T-cell and Retrovirus Studies Immunology 0 works
  7. 7 Cancer, Lipids, and Metabolism Cancer Research 0 works
  8. 8 Colorectal Cancer Treatments and Studies Oncology 0 works
  9. 9 Cancer Cells and Metastasis Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available22.4%not open77.6%

World: 40% of research is openly available.

with international co-authors20.3%domestic only79.7%

World: 18% is written across borders.

How has Cyclacel Pharmaceuticals (United Kingdom)'s research output changed?

Output in 2022-2025 was 46% lower than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cyclacel Pharmaceuticals (United Kingdom) as a percentage of every work published that year, 0.000017% in 2024.

still counting0.00025%0.00050%0.00075%Cyclacel Pharmaceuticals (United Kingdom)0.000012% in 2025200020102020

Fractional works of Cyclacel Pharmaceuticals (United Kingdom) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Dundee

All research institutions in Dundee

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Cyclacel Pharmaceuticals (United Kingdom). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.